Join us this afternoon at 4:30p.m. ET for our Fourth Quarter and Year End 2024 earnings call. https://ow.ly/Upb050VkfaH #earnings #biotech
Trevi Therapeutics, Inc.
Biotechnology Research
New Haven, CT 3,203 followers
Clinical-stage biopharmaceutical company
About us
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.
- Website
-
http://trevitherapeutics.com
External link for Trevi Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New Haven, CT
- Type
- Privately Held
- Founded
- 2011
Locations
-
Primary
Get directions
195 Church Street
14th Floor
New Haven, CT 06510, US
Employees at Trevi Therapeutics, Inc.
-
Catherine W.
Snr. Director Clinical Operations at Trevi Therapeutics, Inc.
-
Vandana Mathur, MD FASN
Clinical Drug Development and Strategy Consultant, Transplant Nephrologist and Clinical Trialist with broad range of experience including nephrology,…
-
Pam Nieves
Associate Director, Quality Assurance and Compliance at Trevi Therapeutics, Inc.
-
Jim Cassella
Chief Development Officer at Trevi Therapeutics
Updates
-
Trevi Therapeutics, Inc. reposted this
Looking for a new opportunity to advance your career? Please take a look at the job below and let us know if you are interested.
Trevi is accepting applications for a Director of Medical Affairs! If you or someone you know is looking to join our innovative and passionate team, apply now: https://ow.ly/Uhs950UPSgT #biotech #MedicalAffairs #JobOpening #LifeSci
-
-
At Trevi, we believe in the potential of Haduvio to target chronic cough. Our team is dedicated to advancing research with this exciting investigational agent. To learn more about Haduvio’s central and peripheral KAMA mechanism of action, visit: https://lnkd.in/dA9ScK9q
-
Mark your calendars for Trevi’s Fourth Quarter and Year End 2024 earnings call. https://ow.ly/ehhr50Vg2g2 #biotech #earnings
-
-
We are pleased to share the positive topline results from our Phase 2a RIVER Trial of Haduvio in patients with Refractory Chronic Cough. ✅ Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline ✅ Haduvio showed similar efficacy in patients with moderate or severe cough counts (p<0.0001) ✅ Haduvio is the first and only investigational therapy to show a statistically-significant reduction in chronic cough across both RCC and IPF patients ✅ Patient reported and other secondary outcomes were statistically significant and consistent with the primary endpoint ✅ The safety results of the trial were generally consistent with the known safety profile of Haduvio from previous trials. Join our conference call today, March 10th, at 8:30a.m. ET to hear our senior management and key opinion leader, Professor Jacky Smith, dive deeper into these results! Read our press release here: https://lnkd.in/eiYatYVe #ControllingCough #ClinicalResults #RefractoryChronicCough
-
-
Tune in tomorrow, March 10th at 8:30a.m. ET to hear the topline results for the Phase 2a RIVER Trial of Haduvio in patients with Refractory Chronic Cough. To join the call visit: https://ow.ly/iuck50Veu6R #RefractoryChronicCough #ClinicalTrials
-
-
A HUGE thank you to our incredible team! Your dedication to improving patients’ lives moves innovation forward! #EmployeeAppreciation #NewHaven #Biotech
-
-
The Trevi team is headed to Boston for TD Cowen Inc. 45th Annual Health Care Conference. Lisa Delfini, Trevi CFO, and Farrell Simon, CCO, are excited to connect with investors and discuss Trevi’s commitment to addressing the unmet need in chronic cough. We hope to see you there! #ChronicCough
-
-
Today, we would like to show our support for those living with rare diseases and their loved ones. Clinical research plays a vital role in advancing care and improving outcomes for individuals with rare diseases. At Trevi, we are dedicated to our clinical development in #cough in Idiopathic Pulmonary Fibrosis. Learn more about our current clinical trials at https://ow.ly/W2VR50UQpiH #RareDiseaseDay #ClinicalTrials #CoughinIdiopathicPulmonaryFibrosis #IdiopathicPulmonaryFibrosis
-
-
Exciting discussions ahead this March! Trevi senior leadership looks forward to attending TD Cowen Inc. 45th Annual Health Care Conference, Leerink Partners Global Healthcare Conference and Leerink Partners Mountain Meeting. Attending one of these events? Be sure to connect with our team to learn more about our development in chronic cough. For more details visit https://ow.ly/tLMO50V7zCy #TreviLeadership #Biotech #Healthcare
-